-
Signature
-
/s/ Carolyn M. Rucci, attorney-in-fact for Nicholas Grund
-
Issuer symbol
-
AKBA
-
Transactions as of
-
02 Feb 2026
-
Net transactions value
-
-$117,912
-
Form type
-
4
-
Filing time
-
04 Feb 2026, 16:13:46 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Grund Nicholas |
Chief Commercial Officer |
C/O AKEBIA THERAPEUTICS, INC, 245 FIRST ST., CAMBRIDGE |
/s/ Carolyn M. Rucci, attorney-in-fact for Nicholas Grund |
04 Feb 2026 |
0001661887 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
AKBA |
Common Stock |
Sale |
$74,483 |
-53,585 |
-8.3% |
$1.39 |
592,994 |
02 Feb 2026 |
Direct |
F1, F2 |
| transaction |
AKBA |
Common Stock |
Sale |
$43,429 |
-31,244 |
-5.3% |
$1.39 |
561,750 |
02 Feb 2026 |
Direct |
F1, F3 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: